Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Pimobendan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B known ✓ | Q13370 | 6/20 | 0.83 |
| ▸ | PDE3A known ✓ | Q14432 | 6/20 | 0.83 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.83 |
| ▸ | PDE4A known ✓ | P27815 | 2/20 | 0.57 |
| ▸ | PDE4B known ✓ | Q07343 | 2/20 | 0.57 |
| ▸ | PDE4C known ✓ | Q08493 | 2/20 | 0.57 |
| ▸ | PDE4D known ✓ | Q08499 | 2/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
| ▸ | MAOA | P21397 | 1/20 | 0.83 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | F10 | P00742 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimobendan SCHEMBL29386190 | 0.99 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL15617988 | 0.99 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL14815175 | 0.99 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL2466855 | 0.99 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL27623 | 0.99 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL668129 | 0.98 | PDE3B (0.83) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL1997246 | 0.97 | PDE3B (0.81) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL1993626 | 0.94 | PDE3B (0.77) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL1649737 | 0.91 | PDE3B (1.00) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL9781454 | 0.86 | PDE3B (0.64) | PDE3BPDE3AABCB11MAOAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2338493-A1 | Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use | Eurovet Animal Health B.V. (NL) | 2011-06-29 | — | — | EP | claimed |
| US-20110152283-A1 | CRYSTALLINE PIMOBENDAN, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION AND USE | EUROVET ANIMAL HEALTH B.V. (NL) | 2011-06-23 | — | — | US | claimed |
| CN-106518850-B | A kind of chemical synthesis process of pimobendan | 青岛农业大学 | 2019-04-09 | — | — | CN | disclosed |
| CN-106518850-A | Chemical synthesis method of Pimobendan | 青岛农业大学 | 2017-03-22 | — | — | CN | disclosed |
| US-8680101-B2 | Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use | EUROVET ANIMAL HEALTH B.V. (NL) | 2014-03-25 | — | — | US | disclosed |
| WO-2011124638-A1 | PIMOBENDAN MANUFACTURING PROCESS | NOVARTIS AG (CH) | 2011-10-13 | — | — | WO | disclosed |
| EP-2338493-A1 | Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use | Eurovet Animal Health B.V. (NL) | 2011-06-29 | — | — | EP | disclosed |
| US-20110152283-A1 | CRYSTALLINE PIMOBENDAN, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION AND USE | EUROVET ANIMAL HEALTH B.V. (NL) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152283-A1 | CRYSTALLINE PIMOBENDAN, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION AND USE | PIM1, PIM3, PIM2 | PDE3B 473/4885PDE3A 283/4885ADORA2A 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.